Despite a recent failure as a second-line monotherapy in diffuse B-cell lymphoma (DLBLC), a positive phase 3 combination ...

Amgen has resisted that withdrawal push, prompting the FDA to double down in April with a formal proposal to pull the drug ...

Viridian Therapeutics has scored an FDA approval for Lumvoa to treat thyroid eye disease (TED), triggering competition with ...

Biopharma giants Eli Lilly and Regeneron and rapidly growing contract manufacturers Fujifilm and Cellares, are among the ...

Klick Health has struck its third takeover in 18 months, snapping up Oxford PharmaGenesis to expand its global reach and ...

A Brukinsa regimen has delivered a large progression-free survival (PFS) benefit in what BeOne Medicines called a “new ...

The European Commission has kicked off formal proceedings in an antitrust investigation against Sanofi. The probe surrounds ...

AstraZeneca has impressed oncology patient groups, rising to second place on PatientView’s corporate reputation ranking on the back of strength in breast and lung cancer. | AstraZeneca has impressed ...

Orca Bio has jumped into the commercial market with FDA approval for Tregzi, a first-of-its-kind engineered cell therapy for blood cancer patients requiring transplants.    | Orca Bio has jumped into ...

Driven by personal losses, major unmet needs and a desire to diversify from the crowded oncology market, Fosun Pharma is ...

Four months after Theravance Biopharma shut down its R&D unit, laid off half its staff and signaled it was up for sale, the ...

Bayer has scored a key victory in its defense against Roundup lawsuits as the U.S. Supreme Court has tossed a $1.25 million ...